Around the grounds:
- merck exploring subqu version of keytruda. That frederick is definitely a forward thinker
https://www.fiercepharma.com/pharma/chasing-roche-merck-talks-subcutaneous-keytruda-ahead-phase-3-data-drop
- gilead’s $5b cd47 acquisition continues to go towards the graveyard of failed checkpoint inhibitors. Still dont think the market has turned hot on lag3.
https://www.evaluate.com/node/18519/amp
- various deals for ADC drugs by big pharma recently. Immuteps needs to get a foot in this space to showcase efti versatility.
Overnight Market report, page-1318
-
- There are more pages in this discussion • 1,462 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add IMM (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
29.5¢ |
Change
-0.040(11.9%) |
Mkt cap ! $428.5M | |||
| Open | High | Low | Value | Volume |
| 32.0¢ | 33.0¢ | 28.0¢ | $7.278M | 23.75M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 4 | 53192 | 29.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 30.5¢ | 41048 | 1 |
View Market Depth
| Last trade - 16.10pm 28/06/2024 (20 minute delay) ? |
| IMM (ASX) Chart |